Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waxman/Hatch Changes Make “Reverse Payments” Less Likely, FTC Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The Waxman/Hatch reforms included in the 2003 Medicare Modernization Act make "reverse payment" settlements of patent litigation less likely, the Federal Trade Commission says in a Supreme Court filing.

You may also be interested in...



Eleven Brand/Generic Drug Patent Settlements Reported To FTC Since January

None of those settlements involved “reverse payments,” FTC staff attorney Kades says. In total, 17 agreements have been reported to FTC since January.

Eleven Brand/Generic Drug Patent Settlements Reported To FTC Since January

None of those settlements involved “reverse payments,” FTC staff attorney Kades says. In total, 17 agreements have been reported to FTC since January.

Cardizem CD Antitrust Ruling Should Stand, FTC Tells Supreme Court

Key aspects of the agreement between Andrx and Hoechst Marion Roussel, such as "reverse payments" and interim settlement, are unlikely to arise in future deals between brand and generic companies, the Federal Trade Commission and Solicitor General tell the high court.

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel